13 Both groups showed similar, highly significant improvements in the primary outcome measure (Positive and Negative Syndrome Scale total score versus baseline scores), but CBD displayed a markedly superior adverse effect profile. 13 The second positive trial explored the safety and effectiveness of CBD as an adjunct to conventional antipsychotics in 88 patients with schizophrenia over a period of 6 weeks. 1 The results showed significant reductions in positive psychotic symptoms and higher clinician-rated global improvement scores.
← all excerpts
The antipsychotic potential of cannabidiol: clinical implications for patients with psychosis and comorbid cannabis use disorder.
1
—
—